• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Ascentage Pharma To Unveil 2025 Financials And Business Updates

    GLOBENEWSWIRE

    Ascentage Pharma Joins Three Investor Conferences

    GLOBENEWSWIRE

    Ascentage Pharma Joins Guggenheim Biotech Summit 2026

    GLOBENEWSWIRE

    Ascentage Announces IND Clearance by China CDE for APG-3288

    GLOBENEWSWIRE

    Ascentage Pharma Secures FDA IND Clearance for BTK Degrader

    GLOBENEWSWIRE

    Ascentage Pharma Update Olverembatinib Data In 2nd-Line Treatment

    GLOBENEWSWIRE

    Ascentage Pharma Reveals 4-Year Data On Olverembatinib

    GLOBENEWSWIRE

    In Diagnosed Ph+ ALL, Olverembatinib Yields >60% MRD-Neg CR Rate

    GLOBENEWSWIRE

    Ascentage Pharma Reveals Positive Results From Lisaftoclax Study

    GLOBENEWSWIRE

    Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting 2025

    GLOBENEWSWIRE

    Ascentage Pharma Publishes Olverembatinib Phase Ib Data

    GLOBENEWSWIRE

    Ascentage Pharma To Present Olverembatinib Data & POLARIS-1 Study

    GLOBENEWSWIRE

    Ascentage Pharma To Present Lisaftoclax Clinical Study Data

    GLOBENEWSWIRE

    Ascentage Pharma to Report 2025 Interim Results, Give Update

    GLOBENEWSWIRE

    Ascentage Pharma to Participate in Evercore China Biotech Summit

    GLOBENEWSWIRE

    Ascentage Pharma Joins BTIG Virtual Biotech Conference 2025

    GLOBENEWSWIRE

    China NMPA Approves Ascentage Pharma`s Lisaftoclax

    GLOBENEWSWIRE

    Ascentage Pharma’s US Shares Climb After $126 M IPO

    FIERCE BIOTECH

    Oral Report Featuring Data of Olverembatinib in Patients with Ph+ ALL Presented

    PR NEWSWIRE

    Ascentage Pharma Presents Updated Data from US Study of Olverembatinib

    PR NEWSWIRE

    First Patient Dosed in the Registrational Phase III Study of Olverembatinib

    PR NEWSWIRE

    Registrational Pivotal PhIII Study of Olverembatinib for First-Line Treatment

    PR NEWSWIRE

    Registrational PIII Study of Olverembatinib for First-Line Treatment of Ph+ ALL

    PR NEWSWIRE

    Olverembatinib Included into the 2022 National Reimbursement Drug List

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.